COMPPARE
Brief description of study
This study is a comparison of patient-centric outcomes between parallel cohorts of men with prostate cancer treated using intensity-modulated radiation therapy techniques. This study includes a pre-specified randomized comparison of standard fractionation and moderate hypofractionation dose schemes within the proton therapy cohort. In addition, subgroup analyses will include a comparison of outcomes by race ,comorbidity score, age, and prostate cancer aggressiveness for all endpoints.
Detailed description of study
Participants will be paid by with a $50
gift card after the following are completed:
1. Pretreatment Patient Surveys
2. First On-Treatment Survey
3. Data confirmed by Study Team
They will also receive $50 for
completing questionnaires at the 3-month and annual follow-up visits for a total of up to
$250 during the first 3 years of participation in the study. They may receive a total of up
to $600 over the entire 10 years, depending on their participation
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
prostate cancer,cancer,non-metastatic,adenocarcinoma
-
Age: Between 30 Years - 80 Years
-
Gender: All
Some criteria are listed below, final eligibility decision is made by protocol physician and trial team:
- Candidate for definitive prostate radiotherapy (either IMRT or proton)
- Patients to be treated with IMRT should have all treatment planned with IMRT;
- patients to be treated with protons should have all treatment planned with protons(including pelvic nodes if treated).
- Men diagnosed with adenocarcinoma of the prostate who have not received previous treatment with the exception of short-term(≤6 months) ADT according to NCCN guidelines(Appendix 6).
- Localized prostate cancer,as confirmed by staging (Appendices 1 and 2) with PSA, biopsy, Gleason score, DRE, and clinical stage.
Updated on
10 Jun 2021.
Study ID: 832798
